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ABSTRACT 
In case of psychiatric treatment immediate release of drug from the dosage form is required. Fast dissolving dosage forms are gaining 
popularity in recent time, as this dosage forms requires no water for administration. Oral films dissolve rapidly along with drug in mouth and 
majority of the drug is absorbed through buccal/oral mucosa in to systemic circulation avoiding first pass metabolism. Olanzapine is a 
thienobenzodiazepine class of drugs, which has been approved by the FDA, for the treatment of schizophrenia, depressive episodes associated 
with bipolar disorder, acute manic episodes and maintenance treatment in bipolar disorder. The absolute bioavailability is only approximately 
31.5% due to extensive hepatic metabolism. Thus the objective of the present study was to formulate and evaluate fast dissolving oral films of 
Olanzapine to improve water solubility, dissolution rate, oral bioavailability and reduction of first pass metabolism and increase patient’s 
compliance. Oral fast dissolving films prepared by solvent casting method using water and 95% ethanol as solvents and HPMC as film forming 
polymer. PEG 400 was the selected plasticizers, Superdisintegrants such as croscarmellose sodium (CCS) and sodium starch glyc olate (SSG) 
alone and also in combinations was incorporated to achieve the aim. The prepared films were evaluated for the drug content, weight variation, 
film thickness, disintegration time, folding endurance, percentage of moisture content and in vitro dissolution studies. Among all, the 
formulation F4 was found to be best formulation which releases 98.78 % of the drug within 15 min and disintegration time is 4 2 sec. which was 
significantly high when compared to other formulation. The data obtained from In-vitro release were fitted into the various kinetic models such 
as Zero Order, Higuchi, First Order and Korsmeyer–Peppas Model in order to determine the mechanism of drug release. When the regression 
coefficient values compared, it was observed that ‘r’ values of formulation F4 was maximum i.e 0.974 hence indicating drug release from 
formulations was found to follow first order drug release kinetics.  
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INTRODUCTION 
Typical antipsychotic drugs are usually classified by their 
chemical structure and the potency of binding to the 
dopamine type 2 (D2) receptors, while new antipsychotic 
agents differ from selective dopamine antagonist in having a 
broader receptor affinity and hence called atypical 
antipsychotics. The atypical antipsychotics are 
characterized by improved clinical efficacy against 
schizophrenia and bipolar disorders with fewer side effects 
such as hallucinations and delusions1. These are also better 
than the typical analogs at relieving the negative symptoms 
of the illness, such as withdrawal, thinking problems, and 
lack of energy2. Olanzapine is one of the recent atypical 
antipsychotics that belongs to the thienobenzodiazepine-
class (2-methyl-4-(4-methyl-1-piperazinyl)-10Hthieno-[2,3-
b][1,5]  benzodiazepine). It is widely used in the treatment 
of schizophrenia and acute mixed or manic episodes. It is 
highly efficient with no or minimal side effects such as 
weight gain and agranulocytosis being similar to the first 
line treatment such as clozapine3. However, Olanzapine 
exhibits very slight solubility in water and suffers from 
extensive first pass metabolism and therefore, possesses 
low bioavailability (40%) after oral administration4. The 
pharmacokinetics of Olanzapine is linear and dose 
proportional within the approved dosage range from 1 mg 
up to 20 mg. direct glucuronidation and CYP1A2 mediated 
oxidation are the primary metabolic pathways for 
Olanzapine. Phenotypic difference for CYP1A2 between 
races has been reported.  Numerous trials were reported in 
the literature for improving bioavailability of Olanzapine 
using solid lipid nanoparticles or through formation of solid 
dispersions with various polymeric carriers5-7.  For the past 
one decade, there has been an enhanced demand for more 
patient-friendly and compliant dosage forms. As a result, the 
demand for developing new technologies has been 
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increasing annually. Orally disintegrating films (ODF) have 
carved a niche amongst the oral drug delivery systems due 
to their high patient compliance8-10. United States Food and 
Drug Administration (USFDA) defined the fast dissolving 
oral thin films as a thin, flexible, non-friable polymeric film 
strip containing one or more dispersed/dissolved active 
pharmaceutical ingredients, which is intended to be placed 
on the tongue for rapid in vitro disintegration or dissolution 
in the saliva prior to swallowing for delivery into the 
gastrointestinal tract11. The objective of the present 
research work was to develop fast dissolving oral films of 
Olanzapine disintegrating within 45s to enhance the 
convenience of administration to the patients to improve 
compliance. The formulation developed was simple, easy to 
prepare and economical with great applicability and also 
giving faster in vitro drug dissolution rate as compared to 
the commercially available immediate release tablets. 
MATERIALS AND METHODS  
Materials 
Olanzapine was obtained as gift sample from Bioplus life 
science, Bangalore India. HPMC was procured from 
Qualikems fine chem. Pvt Ltd Vadodhara. PEG400, sodium 
starch glycolate, croscarmellose sodium was obtained from 
S.D fine chemicals limited, Mumbai. Citric acid, ethanol was 
obtained from Loba Chemical Pvt Ltd (Mumbai, India). 
Hydrochloric acid, KH2 PO4, NaoH was obtained from S. D. 
Fine Chem. Ltd., Mumbai. All other chemical were purchased 
from Hi Media, Mumbai. Double distilled water was 
prepared freshly and used whenever required. All the 
chemicals used in this work were of analytical grade. 
Preformulation studies 
Standardization of Olanzapine by UV-Visible 
spectrophotometry 
Preparation of stock solution: Stock solution 1000μg/ml 
Olanzapine was prepared in phosphate buffer pH 6.8 
solutions. This solution was suitably diluted with buffer 
solution to obtain a concentration of 15μg/ml. The resultant 
solution was scanned in the range of 200-400 nm using UV 
double beam spectrophotometer (Labindia 3000+, 
Mumbai). 
Standard calibration of Olanzapine: From stock solutions 
of Olanzapine 1 ml was taken and diluted up to 10 ml. from 
this solution 0.5, 1.0, 1.5, 2.0 and 2.5 ml solutions were 
transferred to 10ml volumetric flasks and make up the 
volume up to 10 ml with Phosphate buffer pH 6.8, gives 
standard drug solution of 5, 10, 15, 20, 25μg/ ml 
concentration, absorbance was measured at 226nm. 
FTIR Spectroscopy  
Identification of Olanzapine was done by FTIR spectroscopy 
with respect to marker compound. Olanzapine was obtained 
as Yellow crystalline powder. It was identified from the 
result of IR spectrum as per specification. 
Formulation development of oral film of Olanzapine 
Solvent casting technique 
Drug (Olanzapine) containing fast dissolving films were 
fabricated by the solvent casting method12.The optimized 
amount of HPMC was dissolved in 5ml of water and stirrer 
continuously for 1 hour, optimized amount of plasticizer 
and drug were dissolved in 95% ethanol and then added to 
the polymeric solution, Polymeric solution was stirred for 
30 min using magnetic stirrer and was kept in undisturbed 
condition till the entrapped air bubbles were removed. The 
aqueous solution was casted in a glass moulds having 2.5 x 
2.5 cm * 10 films area and was dried at controlled room 
temperature (25°-30°C, 45 %RH) as well as at increased 
temperature (microwave oven). The film took 
approximately 48 hr to dry at controlled room temperature. 
The dried film was carefully removed from the glass plates 
and was cut into size required for testing. The films were 
stored in air tight plastic bags till further use. Formulations 
were prepared using HPMC K15, PEG-400, SSG and CCS at 
different drug: polymer ratios. The compositions of the 
formulations were shown in table 1. 
 
Table 1 Formulation of olanzapine oral fast dissolving films 
Name of ingredients 
(mg) 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
Olanzapine 60 60 60 60 60 60 
HPMC 250 500 750 250 500 750 
PEG-400 150 150 150 150 150 150 
SSG 150 200 250 - - - 
CCS - - - 150 200 250 
Citric acid 100 100 100 100 100 100 
Glycerin - - - - - - 
DM water  qs to (ml) - - - - - - 
 
Dose calculations 
 Width of the plate = 5cm 
 Length of the plate = 12cm 
 No. of 2.5 x 2.5 cm2 films present whole plate = 12 
 Each film contains 25 mg of drug. 
 12 no. of films contains mg of drug? = 5×12 = 60mg 
 The amount of drug added in each plate was 
approximately equal to 60mg. 
Evaluation 
The formulations were evaluated by the following tests13-16. 
Thickness 
Randomly 10 films were selected and thickness was 
measured using vernier calliper at three different places. 
Weight variation  
For each formulation, three randomly selected patches 
were used. For weight variation test, 10 films from each 
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batch were weighed individually by digital electronic 
balance and the average weight was calculated. 
Folding endurance 
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film 
could be folded at the same place without breaking cracking 
gave the value of folding endurance.  
Percentage of moisture content 
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight 
with respect to final weight.  
Drug content analysis 
The patches (n = 3) of specified area were taken into a 10 
ml volumetric flask and dissolved in methanol and volume 
was made up with 10 ml methanol. Subsequent dilutions 
were made and analyzed by UV spectrophotometer at 
226nm.  
Disintegrating time 
The most important criteria of present work are to that 
dosage form should be dissolved within few seconds. The 
incorporation of super disintegrating agent to minimizes 
the disintegrating time. Three super disintegrating agent 
were selected for this work. The film of (4.15cm2) size (unit 
dose) was placed on a petridish containing 10 ml of distilled 
water. The time required for the film to break was noted as 
cursive in vitro disintegration time. 
In vitro dissolution study  
The in vitro dissolution test was performed using the 
USPXXX dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5° C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 
6.8). Film size required for dose delivery (2.5×2.5 cm2) was 
used. Five ml aliquot of dissolution media was collected at 
time intervals of 1, 2, 5, 10 and 15 minutes and replaced 
with equal volumes of phosphate buffer (pH 6.8). The 
collected samples were filtered through 0.45 μm membrane 
filter and the concentration of the dissolved Olanzapine was 
determined using UV-Visible spectrophotometer at 226nm. 
The results were presented as an average of three such 
concentrations. 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of one, two and 
three months at 40±2oC temperature and 75±5% relative 
humidity for a period 3 months. The % Assay of formulation 
was determined by U.V. spectrophotometer using 
calibration curve method. The % assay of film was found to 
slightly decrease at higher temperature.  
RESULTS AND DISCUSSION  
Identification of Olanzapine was done by FTIR spectroscopy 
with respect to marker compound. It was identified from 
the result of IR spectrum as per specification fig. 1. 
Solubility of Olanzapine was freely soluble in ethanol and 
methanol, sparingly soluble in 0.1N HCL and chloroform, 
soluble in 6.8 pH phosphate buffers, insoluble in water. λ max 
of Olanzapine was found to be 226 nm by using U.V. 
spectrophotometer (Labindia-3000+). The calibration curve 
of Olanzapine was found to be linear in the concentration 
range of 5-25µg/ml at 226 nm fig. 2. The general 
appearance, assay, weight variation and thickness of all the 
films were within acceptable limits table 2. The results for 
tensile strength, folding endurance, disintegrating time and 
% of moisture were shown in table 3. Tensile strength value 
of optimized formulation (F4) was 1.236±0.045 kg/cm2 and 
folding endurance was 145± 8.55. The formulations 
containing CCS were showing good results compared to 
SSG. The assay values of all the formulations were ranging 
from 97.65 to 99.05 %. The disintegration time was ranging 
between 42 to more than 73 sec. The final formulation 
shows better drug release (98.78%) compared to other 
formulation within 15 m (Table 4). The cumulative 
percentage (%) drug release profile and the assay of the F4 
formulation films indicates that the drug remain stable 
under the ASC without any significant change in its release 
profile and the drug content. From the stability studies it 
was clearly observed that the drug showed good stability 
after subjecting to accelerated stress conditions and the 
polymers shown significantly compatibility with the drug. 
The kinetic data of optimized formulation F4 was given in 
table 5and fig 3, 4. It was fallow first order drug release. 
 
 
Fig. 1 FT-IR Spectrum of pure drug  
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Fig. 2 Calibration curve of olanzapine in phosphate buffer ph 6.8 at 226 nm 
Table 2 Result of general appearance, thickness, weight variation and % assay 
F. code General 
Appearance 
Thickness in 
µm 
Weight(mg) Mean 
± S.D 
% Assay 
F1 Translucent 45±5 88±1 98.89±0.13 
F2 Translucent 48±3 93±4 97.65±0.22 
F3 Translucent 52±1 95±3 98.85±0.31 
F4 Translucent 42±4 85±6 99.05±0.25 
F5 Translucent 44±2 90±5 98.98±0.15 
F6 Translucent 49±3 93±3 98.78±0.13 
 
Table 3 Result of folding endurance, disintegrating time, tensile strength &% of moisture content 
F. code Folding 
endurance 
(Times) 
Disintegrating 
time (Sec) 
Tensile strength  
in  kg/cm2 
% of moisture 
content 
F1 125± 9.87 69±4 1.105±0.056 2.45±0.111 
F2 135± 4.56 73±6 1.241±0.045 2.22±0.101 
F3 132± 6.45 65±7 1.265±0.012 1.98±0.142 
F4 145± 8.55 42±6 1.236±0.045 1.45±0.156 
F5 165± 7.67 55±4 1.165±0.065 2.23±0.136 
F6 147± 5.29 63±5 1.145±0.045 2.65±0.145 
 
Table 4 Results of In-Vitro release study of optimized 
formulation F4 
S. No. Time (Min.) Cum % Drug release 
1. 1 22.45 
2. 2 45.65 
3. 5 75.65 
4. 10 89.98 
5. 15 98.78 
 
Table 5 Kinetics data of optimized formulation F4 
Formulation Regression 
Coefficient 
Zero 
order 
First 
order 
F4 r2 0.829 0.974 
 
 
Fig. 3 Zero order release kinetics of optimized 
formulation F4
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Fig. 4 First order release kinetics of optimized 
formulation F4 
CONCLUSION 
From present study it can be concluded that oral fast 
dissolving films are superior in drug release. The films 
prepared by HPMC and PEG 400 had shown good 
mechanical strength, drug release, disintegration time and 
stability. F4 formulation is considered as the best according 
to the obtained results with less disintegrating time and 
complete drug release in 15 min. Percent drug release and 
disintegration time was taken as responses for study which 
were found within the accepted ranges. As the 
concentration of CCS was increased, both the disintegration 
and the drug release rates increased. The disintegration and 
release rates were found to be faster for films prepared 
with lowest concentration of HPMC along with maximum 
concentration of superdisintegrants. Olanzapine 
administered in the form of fast dissolving films will be 
potential novel drug dosage form for pediatric, geriatric, 
psychiatric and also for general population by providing 
faster release and better patient compliance. Stability 
studies indicated F4 was stable for 90 days. Hence, there is 
a lot of scope for future in vivo studies. 
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